• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip CEO Dave Gentry Invited to Join Forbes Business Council

    1/25/23 8:00:00 AM ET
    $AREC
    $BIVI
    $GNS
    $RVPH
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AREC alert in real time by email

    ORLANDO, FL / ACCESSWIRE / January 25, 2023 / RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council.

    The Forbes Business Council committee invited Gentry to join the elite group of business leaders in recognition of his passion for helping entrepreneurs achieve success. The invitation-only community is made up of successful business owners and executives who have been chosen based on their accomplishments and experience.

    As a member, Gentry will be able to leverage the Forbes Business Council's collective resources to help foster growth in the RedChip Companies community. He will also be able to participate in exclusive events, such as invite-only webinars and podcasts, publish expert insights as a contributing writer on the Forbes platform, access a private community of members, and more.

    Gentry commented, "I look forward to sharing insights gained from my decades of experience working with executives in the small-cap markets. I believe this is a great opportunity to enhance my contributions to the entrepreneurial spirit that drives business innovations globally, while also gaining valuable new insights from industry veterans."

    Gentry is the author of Small Stocks, Big Money, a Wiley-published book of interviews with the world's most successful small-cap investors. He has been a consultant to more than 1,000 public companies and assisted dozens of public companies in the up-listing and capital-raising process. In 2012 he founded The RedChip Money Report™, a weekly cable TV financial news show broadcast in 177 million homes. He has appeared on CNBC and Fox Business News and is widely known as a thought leader in the small-cap space.

    Gentry has been a presenter at the New York Society of Security Analysts, Deal Flow Media conferences, and other small-cap conferences, and he has rung the NASDAQ bell on three occasions. In 2011, he was honored by Inc. Magazine as CEO of one of the fastest-growing private companies in America. In 1996, he won the Republican nomination in the 5th District of Florida for the United States House of Representatives. In 1994 he co-founded the First Amendment Coalition, an independent, nonprofit, collegiate-based student organization, and received national and international attention for his work defending free speech on college campuses. Gentry's activism led to his book 100+ Cases of Campus Censorship, published by David Horowitz's Second Thoughts Books. Gentry earned his Master of Education from the University of Florida in 1993.

    RedChip currently represents more than 70 clients, including some of the best emerging growth companies in the small-cap space, such as Genius Group (NYSE:GNS), Reviva Pharmaceuticals (NASDAQ:RVPH), Zomedica (NYSE:ZOM), BioVie (NASDAQ:BIVI), and American Resources Corporation (NASDAQ:AREC).

    About Forbes Business Council

    The Forbes Business Council is an exclusive platform that brings together successful business owners and executives from all over the world. Members are handpicked by the Forbes Business Council committee based on their accomplishments, experience, and commitment to helping entrepreneurs reach their goals.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Matt Sheldon
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/736680/RedChip-CEO-Dave-Gentry-Invited-to-Join-Forbes-Business-Council

    Get the next $AREC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AREC
    $BIVI
    $GNS
    $RVPH

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    BioVie Inc.
    $BIVI
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    1/24/2022$10.00Buy
    HC Wainwright & Co.
    BioVie Inc.
    $BIVI
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    American Resources Corporation
    $AREC
    11/16/2021$4.00 → $3.75Buy
    HC Wainwright & Co.
    American Resources Corporation
    $AREC
    8/18/2021$4.50 → $4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AREC
    $BIVI
    $GNS
    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genius Group Provides Update on Legal Cases

    SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, has scheduled a Live Spaces call on X.com at 9.00am Eastern Time, August 26, 2025 to provide a legal update and host a Q&A on the Company's market manipulation lawsuit and RICO lawsuit. The Live Spaces call will be attended by the Company's CEO, Roger James Hamilton, and the Company's litigation attorneys, James Wes Christian and Mark R Basile Esq. It will be hosted by Board Advisor, Kevin Malone. Arbitration and Related Preliminary Injunction (PI) Appeal with LZGI With relation to the Company's arbitration and related preli

    8/18/25 8:36:18 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    – Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine's path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 – CUPERTINO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc.

    8/14/25 4:25:11 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Reviva Pharmaceuticals with a new price target

    ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    9/20/23 7:22:47 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target

    The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00

    6/8/23 7:41:12 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dawson James initiated coverage on Zomedica Pharmaceuticals with a new price target

    Dawson James initiated coverage of Zomedica Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    1/6/23 9:00:39 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

    4/A - Zomedica Corp. (0001684144) (Issuer)

    3/27/25 9:56:49 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    SEC Filings

    View All

    SEC Form 10-Q filed by American Resources Corporation

    10-Q - American Resources Corp (0001590715) (Filer)

    8/19/25 6:17:34 AM ET
    $AREC
    Coal Mining
    Energy

    SEC Form 10-K filed by BioVie Inc.

    10-K - BIOVIE INC. (0001580149) (Filer)

    8/15/25 5:05:22 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by American Resources Corporation

    NT 10-Q - American Resources Corp (0001590715) (Filer)

    8/14/25 5:00:17 PM ET
    $AREC
    Coal Mining
    Energy

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

    4/A - Zomedica Corp. (0001684144) (Issuer)

    3/27/25 9:56:49 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Leadership Updates

    Live Leadership Updates

    View All

    Genius Group Board appoints Kevin Malone as Board Advisor.

    SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Kevin Malone as an advisor to the Board. Mr. Malone brings experience advising companies and investors on fighting market manipulation, together with over 40 years of family experience in wealth management Kevin Malone is the CEO and President of Malone Wealth, a Registered Investment Advisory Firm, managing a range of investments in companies focused at AI, Web3 and exponential technology. He also founded the Malone Wealth Charitable Fund with a mission to empower the next generation with

    6/30/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

    The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

    5/5/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    12/20/24 7:00:00 AM ET
    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Financials

    Live finance-specific insights

    View All

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

    CARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Decreases Biological Age Acceleration in Alzheimer's Disease" at the 2nd World Conference on Aging and Gerentology (WCAG-2025) in Rome, Italy July 14-15, 2025. As the body ages, a natural process called DNA methylation occurs and adds "methyl" groups to the surface of DNA. Accumulated methylation has the impact of interfering with how DNA is decoded and thus has been shown to impact a wide range of dis

    7/24/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

    CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer's Disease (AD) treatment that focuses on changing one gene product (e.g., amyloid, p-Tau) at a time, bezisterim modulates inflammation and is believed to help reestablish homeostasis and small changes in

    7/9/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genius Group Limited

    SC 13G - Genius Group Ltd (0001847806) (Subject)

    11/14/24 5:32:28 PM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 4:15:57 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care